Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1065-1069

  Garg, S K ^a   Buse, J B ^b   Skyler, J S ^c   Vaughn, D E ^d   Muchmore, D B ^d  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Halozyme Therapeutics Inc   (United States)

Author keywords

Insulin delivery; Insulin therapy; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN LISPRO; RECOMBINANT HUMAN HYALURONIDASE PLUS RECOMBINANT HUMAN INSULIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HUMAN INSULIN; HYALURONOGLUCOSAMINIDASE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEMATOMA; HEMATOPNEUMOTHORAX; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE BLEEDING; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; TITRIMETRY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; MEAL; POSTPRANDIAL STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN LISPRO; INSULIN, REGULAR, HUMAN; MALE; MEALS; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84914142888     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12315     Document Type: Article

References (14)

1. ADA. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33: S11-S61.
2. Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218.
3. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-2264.
4. McAulay V, Frier BM. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003; 4: 1141-1156.
5. Baxter Healthcare Corporation. Hylenex recombinant (hyaluronidase human injection) 150 USP units/mL [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation, 2009.
6. European Medicines Agency. European summary for the public: HyQvia (human normal immunoglobulin). Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002491/WC500143854.pdf. Accessed 4 June 2014.
7. Chain E, Duthie ES. Identity of hyaluronidase and spreading factor. Br J Exp Pathol 1941; 21: 324-338.
8. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4: 427-440.
9. Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114: 230-241.
10. Vaughn DE, Yocum RC, Muchmore DB et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009; 11: 345-352.
11. Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol 2010; 4: 419-428.
12. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011; 34: 666-668.
13. Hompesch M, Muchmore D, Morrow L, Mongiovi D, Vaughan D. Accelerated insulin pharmacokinetics and improved glycemic control in T1DM patients by coadministration of prandial insulin with recombinant human hyaluronidase. Diabetes 2009; 58(Suppl. 1): A121.
14. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available from URL: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 15 August 2012.